Dr Ashwin Oommen Philips
Associate ProfessorArea of Interest
Solid tumor oncology
Immuno oncology
Pprecision oncology
Metastatic diseases and Palliative Care
Clinical research and clinical trials
| Qualification | Specialization | Institution | Year of Passing |
|---|---|---|---|
| MBBS | DR MGR UNIVERSITY | 2007 | |
| DNB | Medicine | NATIONAL BOARD EXAMINATION. | 2013 |
| DM | Medical Oncology | CANCER INSTITUTE ADYAR. | 2018 |
| Designation | Institution | Tenure |
|---|---|---|
| Associate Professor | Amala Institute of Medical Sciences,Thrissur | |
| Associate Professor | CMC Ludhiana | |
| Assistant Professor | Christian medical college, Ludhiana, Punjab | |
| Senior Resident | Cancer Institute Adyar , Chennai | |
| Senior Resident | Christian medical college Ludhiana Punjab |
- Ashwin P, Venkatraman et al- Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome, Indian Journal of Hematology and Blood Transfusion 34(1) · March 2018
- Ashwin P, Venkatraman et al -Experience with pemetrexed maintenance with NSCLC from tertiary level hospital.Dr MGR University e-journal.
- Eqbal A, Goodliffe L, Masoom H, Ashwin P et al. The Syncopal Sarcoma. J Am Coll Cardiol Case Rep. 2022 Aug, 4 (16) 1037–1041
- Mall A, Negi P, Philip AO, Kingsley PA. Induction chemotherapy in head and neck cancers – Boon or bane? J Can Res Ther 2023;19:420-5.
- Philips A, Soumya P, Sunu C, Moharana, et al Real-World Experiences of Next-Generation Sequencing in Oncology: From an Indian Multicenter Registry andCollaborative Centers. Indian Journal of Medical and Paediatric Oncology. 10.1055/s-0044-1779275.
| Award/Achievements | Award Provider | Year |
|---|---|---|
| Institutional Principal Investigator from Christian Medical College, Ludhiana for DBT funded 1.58 crore budget grant to establish clinical trial network at the national level entitled “Network Of Oncology Clinical Trials In India, NOCI” .2018 | 2018 | |
| Co investigator for the Crocodile study-Colorectal cancer in India: catastrophic expenditure and referral pathways influence on presentation and treatment | 2009 | |
| Co investigator for the “ACCESS India Study- Accessing Childhood Cancer Services in India” InPOG Registration Number- InPOG-ACC-16-02 | 2015 | |
| ISMPO- ESMO Asia travel grant December 2 nd to 4th December 2022 -abstract titled ``Next Generation Sequencing in Oncology -Real world data from an Indian Multicenter Registry". | 2022 | |
| 3rd Rank in the Paper presentation of Gynaecologic Cancer category - Real world clinical profile and outcomes of malignant ovarian tumors in adolescent and young adults report from the multicentric network of oncology clinical trials India (NOCI) cancer | 2022 | |
| Principal Investigator from CMC Ludhiana- Radio genomics Project with IIT Jodphur | 2022 | |
| Organizing Secretary Oswal Cancer Conclave 10 th December 2022. | 2022 | |
| ESMO Immuno-Oncology Preceptorship travel grant November 29 th to December 1 st 2022. | 2022 | |
| Organizing Secretary Oswal Cancer Conclave 20th August 2023 | 2023 | |
| Co investigator for ICMR Cancer Registry from CMC Ludhiana | 2023 | |
| Co Investigator for the ICMR grant from CMC Ludhiana Titled-"An open-labelled multi-centric non-inferiority randomized controlled trial to compare sublingual Buprenorphine versus oral Tramadol for cancer pain" | 2023 | |
| Primary Investigator from CMC Ludhiana –“Randomised Double Blind Placebo Controlled Phase III study Of Daralutamide in addition to Adrogen Deprivation therapy Vs Placebo +ADT in men with metastatic Hormone sensitive prostate cancer. | 2023 | |
| Primary Investigator from CMC Ludhiana-“Phase 2 clinical study to evaluate the efficacy and safety of NRC-2694-A in patients with recurrent head and neck squamous cell carcinoma | 2023 | |
| Primary Investigator from Mohandai Cancer Hospital-“Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevac- izumab) when compared to Avastin®-EU in Combination with Carboplatin and Paclitax | 2023 | |
| Primary Investigator from MohanDai Cancer Hospital-A Multicenter, Double-Blind, Randomized, Parallel-Group, Active-Controlled, Two Part, Phase III, Global Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BP 02 (Trastuzumab) in comparison wit | 2023 | |
| Primary Investigator from CMC Ludhiana- SPEAR (Study of PIK3CA mutations and Effectiveness and tolerability outcomes of Alpelisib in Real-world) A descriptive study of PIK3CA mutations and outcomes with Alpelisib in patients with HR-positive and HER2-nega | 2023 | |
| Primary Investigator from CMC Ludhiana-A multi-center, investigator-initiated, open label, randomized, parallel group, -superiority trial to investigate the efficacy and safety of scalp cooling system in the prevention of chemotherapy induced alopecia in | 2023 | |
| Primary Investigator from CMC Ludhiana -A Prospective, Randomized, Multicenter, Comparative Double-blind, Parallel study to Evaluate the efficacy, Safety,_ Pharmacokinetics; and Immunogenicity of Biosimilar Pertuzumab (ENZENE) with Reference Pertuzumab (P | 2023 | |
| Basic Course In Research Methodology -passed December 2020 | 2020 | |
| Revised Basic Course In Medical Education- Feburary 2021 | 2021 | |
| Attended Introductory Course on Research Methodology and Biostatistics under Dr. Padam Singh Research & Development Scheme, Organised by joint state Training Center of Institute of Applied Statistics and Christian Medical College and Hospital, Ludhia | 2022 | |
| Foundation Course in Palliative medicine course September 2022. | 2022 | |
| Advanced course In molecular Oncology (ACMO) | 2022 |